Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer
Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer
RATIONALE: Giving chemotherapy drugs and total-body irradiation before a donor peripheral
 blood stem cell transplant helps stop the growth of cancer cells. It also helps stop the
 patient's immune system from rejecting the donor's stem cells. When the healthy stem cells
 from a donor are infused into the patient they may help the patient's bone marrow make stem
 cells, red blood cells, white blood cells, and platelets.

 PURPOSE: This phase II trial is studying the effectiveness of donor peripheral blood stem
 cell transplant in treating patients with hematologic cancer.
OBJECTIVES:

 -  Determine the efficacy and safety of allogeneic peripheral blood stem cell
 transplantation in achieving engraftment in patients with hematologic malignancy.

 -  Determine the hematopoietic recovery, incidence of chemoradiotherapeutic toxicity,
 relapse, graft-versus-host disease, and survival of patients treated with this regimen.

 OUTLINE: Patients receive a preparative chemoradiotherapeutic regimen and graft-versus-host
 disease prophylaxis prior to transplantation. Patients undergo allogeneic peripheral blood
 stem cell transplantation on day 0.

 Patients are followed every 1-2 weeks for 6 months and at 9, 12, 24, and 36 months.

 PROJECTED ACCRUAL: A total of 62 patients will be accrued for this study within 4 years.
DISEASE CHARACTERISTICS:

 -  Diagnosis of one of the following:

 -  Chronic myelogenous leukemia

 -  Philadelphia chromosome-positive OR

 -  Molecular evidence of bcr/abl gene rearrangement

 -  Acute myeloid leukemia, acute lymphocytic leukemia, lymphoma, histiocytoses,
 myelodysplasia, juvenile chronic myelomonocytic leukemia, aplastic anemia,
 paroxysmal nocturnal hemoglobinuria, or Fanconi's anemia

 -  Confirmed by cytochemistry, immunophenotyping, and/or chromosomal
 abnormalities

 -  Multiple myeloma

 -  Hereditary immunodeficiency disorders

 -  Confirmed by immunologic determination

 -  Sickle cell anemia or beta-thalassemia

 -  Confirmed by hemoglobin electrophoresis

 -  Storage disorders (e.g., Gaucher's disease, Hurler's disease, or metachromatic
 leukodystrophy)

 -  Confirmed by metabolic testing

 -  Other non-malignant conditions

 -  Eligible for allogeneic peripheral blood stem cell or bone marrow transplantation

 PATIENT CHARACTERISTICS:

 Age:

 -  65 and under

 Performance status:

 -  Not specified

 Life expectancy:

 -  Not specified

 Hematopoietic:

 -  Not specified

 Hepatic:

 -  Not specified

 Renal:

 -  Not specified

 PRIOR CONCURRENT THERAPY:

 Biologic therapy

 -  Not specified

 Chemotherapy

 -  Not specified

 Endocrine therapy

 -  Not specified

 Radiotherapy

 -  Not specified

 Surgery

 -  Not specified